secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001104659-24-086369
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec appoints Jeffrey Hackman as CEO, succeeding Rostislav Raykov
-------------------------------------------------------------------

- Hackman named CEO and director effective August 16, 2024; Raykov steps down after 15 years, remains on board.
- Hackman's initial salary $550,000, target bonus 50% of salary, granted 400,000 options vesting over three years.
- Raykov enters separation agreement; acceleration of 292,359 options at weighted avg price $7.50; RSUs intact through April 2027.
- Hackman brings 30+ years commercial oncology experience; previously led U.S. operations at Sigma Tau, Baxalta, Shire, EUSA Pharma.
- Appointment comes as company expands PEDMARK use for cisplatin-induced ototoxicity in pediatric and AYA patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/0001104659-24-086369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924086369/tm2421051d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer